参考文献:Recompensation is defined by resolution of an ascites by no more bleeding for at least 12 months and also resolution of hepatic encephalopathy. It's actually quite fortunate that we have seen with effective antiviral therapies. Both with hepatitis b and also hepatitis c and also in patients who stop alcohol drinking that they can actually recompensate.
Tao L， Yang G， Sun T， et al. Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1. J Hepatol 2023.
Turco L， Reiberger T， Vitale G， et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int 2023.
门静脉血栓是指涉及门静脉主干、脾静脉、肠系膜静脉等在内的门静脉系统血栓，是肝硬化常见并发症之一。1998—2014年美国流行病学调查数据显示，住院肝硬化患者PVT平均患病率为1.5%，病死率波动于9.1%~11.9%。
肝硬化是由一种或多种病因持续或反复作用形成的弥漫性肝纤维化及肝小叶结构紊乱，规范的治疗可有效降低肝硬化患者失代偿及肝癌的发生率。在第九届华夏上海肝病论坛上，首都医科大学附属北京友谊医院贾继东教授针对“肝硬化治疗的共识与争议”进行了精彩讲座，肝胆相照平台特将精华整理成文，以飨读者。
肝硬化是各种慢性肝病发展的晚期阶段，门静脉高压既是肝硬化的结果，也是肝硬化并发症的最主要原因。肝静脉压力梯度是诊断门静脉高压症的金标准，根据“Baveno Ⅶ—门静脉高压症的更新共识”，HVPG>5 mmHg提示窦性门静脉高症;
